Uncategorized

New Delhi: Fusion Micro Finance met the expectations of traders. Affinity Micro Finance Ltd. 324.80-43.20 (-11.74%) TOP INSIGHT Today’s stock price touched a new 52-week low. to view more close Tuesday’s Dalal Street debut of NSE -11.74% was subdued.

The young microfinance player’s stock was listed at a discount of 2% to its issue price of Rs 368 per share, at Rs 359.50 on the National Stock Exchange (NSE) and at Rs 360.50 on the BSE.

The loss for investors increased to more than 7% as the scrip fell another 5% to Rs 341.10, aggravating the pain in the counter.

According to analysts, only high-risk investors should hold the stock in the short- to medium-term, while everyone else should book their losses and sell.

“The company’s margins are still on the decline, and the category of borrowers it caters to poses a risk. Concerns for the business could also arise from an increase in NPAs “Added he. “Applicants for listing gains may continue to hold a stop loss of Rs. 340.”

Fusion Micro Finance’s initial public offering (IPO) was open for subscription from November 2 to 4, during which the company sold its shares for between Rs 350 and Rs 368 each in order to raise Rs 1,104 crore through an initial stake sale.

The issue was subscribed 2.95 times overall, with an 8.6 times subscription for the quota for qualified institutional bidders and a 1.38 times subscription for the HNI portion. Only 51% of the retail investor portion was subscribed.

The grey market was indicating a quiet listing, according to Manoj Dalmia, Founder & Director at Proficient Equities, and the issue did not receive a lot of interest during the bidding.

He continued, “Investors who applied for the shares only to profit from the listing can book at the listing price, while others can hold for a mid-to-long-term.

Fusion Micro Finance, a 1994 corporation, specializes in offering financial services to women business owners who come from economically and socially disadvantaged areas of society.

It has a network of 966 branches, 9,262 permanent employees, and 2.90 million active borrowers spread across 377 districts, 19 states, and union territories.

Investors should invest in other pre-listed financial players or lenders, according to Ravi Singhal, CEO of GCL Securities. Investors should exit at listing, he suggested.

Prior to Fusion Micro Finance’s listing today, CRISIL’s Ratings upgraded its long-term rating on its bank facilities and non-convertible debentures to “CRISIL A/Stable” from “CRISIL A-/Stable.”

To know more about the fundamentals of the stock, click here … To learn more about the stock market courses 2021 , click here

Multibagger pharma stock announces 2:1 bonus shares, and net profit increases 182% in Q2

Zim Laboratories Ltd. is a small-cap company that operates in the pharmaceutical sector with a market valuation of $509.10 Cr. The company also provides finished formulations (FF) and pre-formulation intermediates (PFI) for a number of important therapeutic categories in addition to developing, producing, and delivering unusual generic pharmaceuticals in oral solid doses. A 2:1 bonus share issuance was announced along with the company’s Q2 earnings.

Zim Laboratories’ bonus share information according to data from stock exchanges

3,24,83,876 equity shares worth Rs. 10 each make up the total number of securities proposed for issuance or the approximate total amount for which the securities will be issued.

Whether bonus shares are issued from share premium accounts or free reserves made from profits, the bonus shares will be issued from the securities premium accounts available as of March 31, 2022.

Bonus Ratio: 2:1, or 2 (two) equity shares worth Rs. 10 each for every 1 (one) equity share worth Rs. 10 each that has been fully paid up. Paid-up Pre-Bonus Issue 16,24,19,380 rupees worth of equity shares are divided into 1,62,41,938 shares, each worth 10 rupees. Paid-up Post-Bonus Issue 4,87,25,814 equity shares worth Rs. 10 each make up the share capital of Rs. 48,72,58,140.

Required Free Reserves and/or Share Premium for the Bonus Issue: Rs. 32,48,38,760 would be capitalized from the Securities Premium Account for the issuance of Bonus Shares.

In Q2FY23, the company reported total expenses of 92.54 crores, up from 73.68 crores in Q2FY22, a YoY increase of 25.59%. In Q2FY23, the company reported a profit before tax (PBT) of $8.15 million, up from Q2FY22’s PBT of $2.92 million, a YoY gain of 179.10 percent. In comparison to the net profit of 2 Cr reported in Q2FY22, the company reported a net profit of 5.65 Cr in Q2FY23, an increase of 182.50% YoY. In Q2FY23, the EPS increased to $3.49 per share from $1.24 in Q2FY22 and $3.47 in Q1FY23.

The date that such bonus shares are anticipated to be credited or sent: The Bonus shares will be credited/delivered within two months of the date of the Board approval, or on or before January 11, 2023, subject to obtaining shareholder approval, Statutory/Regulatory approvals, and other approvals, as may be necessary.

Click here to see more fundamentals on the screener app. To learn more about the courses, click here

Separately, the company reported net sales of 99.26 crores in Q2FY23 compared to 75.72 crores in Q2FY22, an increase of 31.08% year over year. In the three months that ended in September 2022, the company reported a net income of $100.70 Cr, up from the 76.61 Cr reported in the same period the previous year. This represents a YoY growth of 31.44%.

On a consolidated basis, the company reported net sales of 99.40 crores in the second quarter of FY23, up from 77.47 crores in the same quarter of FY22, or a YoY increase of 28.30%. In comparison to the 78.34 Cr reported in Q2FY22, the company reported a total income of $100.82 Cr, representing a YoY growth of 286.90%. In Q2FY23, the company reported total expenses of 92.86 crores, up from the 74.14 crores reported in Q2FY22, a YoY gain of 25.24%. In Q2FY23, the company reported a PBT of $7.95 million, up from the $4.20 million reported in Q2FY22, a YoY increase of 89.28%.

Zim Laboratories Ltd.’s shares ended trading on Friday at 313.50 per share, up 0.064% from the previous close of 313.30. Over the last five years, the stock has generated a multi-bagger return of 146.40%, and over the last three years, a multi-bagger return of 282.49%. Over the past year, the stock has produced a multi-bagger return of 150.90%, and YTD in 2022, it has done so with a multi-bagger return of 163.56%.

How to check Divis lab share price – Pharmaceuticals company. Learn why the price of Divis lab is falling. Should you buy, hold or sell this stock?

Before we get started, if you are interested in checking out the fundamentals of the stock, you can check it on the screener app. To learn more about our stock market courses, click here.

Now the main reason for the slum of the Divis lab is Q2 PAT which decreased 18% YOY to rs 493 cr from Rs 606.46 crore.

Profit before taxes fell 19.01% to Rs 615.22 crore in Q2 FY23, from Rs 759.62 crore in Q2 FY22.

During the quarter under review, total expenses increased by 5.81% year on year to Rs 1,319.40 crore. In Q2 FY23, the cost of materials consumed decreased by 6.79% year on year to Rs 817.01 crore, while employee benefit costs increased by 3.63% year on year to Rs 232.12.

In Q2 FY23, the company’s net profit fell 19.71% to Rs 486.85 crore on a 7.34% drop in revenue from operations to Rs 1,823.38 crore compared to Q2 FY22.

Overall, Divis lab share price is trading close to its intrinsic value of 2772. However, quite far from its book value of 457.

Divis lab share price

Currently, the price of the share as of Nov 7, 2022, CMP is 3415. Let’s look at the fundamentals of the stock. Looking at ts shareholding atter.

Shareholding Pattern

Numbers in percentage deals / TRADES

16 recently

Let’s look at the major reason for the fall of this share.

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

If you have a position in this share, you can hold this share. The company is overall profitable.